DIPG Alliance, Singapore's first charitable foundation dedicated to advancing research for Diffuse Intrinsic Pontine Glioma (DIPG) and other paediatric brain cancers, has been established to accelerate research, improve access to emerging therapies and clinical trials, and provide support for children and families affected by these devastating diseases. Diffuse Intrinsic Pontine Glioma (DIPG) is one of the deadliest diagnoses in childhood cancer.
Although newly established, DIPG Alliance is already a strategic partner in KK Women's and Children's Hospital's (KKH) KIND (KKH Integrated Neuro-Oncology Development) Programme, supporting the hospital's efforts to build a sustainable paediatric brain
As part of this partnership, DIPG Alliance initiated and facilitated KKH's onboarding into the Pediatric Neuro-Oncology Consortium (PNOC), an international network dedicated to advancing new therapies for children and young adults with brain tumours. Once onboarding is complete, KKH will be able to participate in international clinical trials, providing eligible children in Singapore and the region with access to promising new treatment options.
Beyond current initiatives, DIPG Alliance is actively exploring and supporting other emerging therapies, including CAR T-cell therapy, as part of its broader commitment to expanding treatment options and accelerating access to innovative therapies for children with DIPG and other paediatric brain cancers.
Looking ahead, DIPG Alliance aims to raise S$5 million over five years to establish Singapore's first enduring paediatric brain
